Buy 2seventy bio (TSVT) on Weakness
This morning, I published my latest recommendation: Buy 2seventy bio (TSVT).
The stock is down 11% because the company announced that it paused a trial of one of its pipeline drugs due to a patient death.
While this is sad news on a personal level, it doesn’t impact my valuation for the stock.
Why?
Because my valuation doesn’t include any “credit” for the pipeline, yet I see almost 200% upside.
Therefore, I would use weakness as a buying opportunity (I did).
